Topical ocular delivery of fluoroquinolones

被引:21
|
作者
Pawar, Pravin [1 ]
Katara, Rajesh [2 ]
Mishra, Sushil [2 ]
Majumdar, Dipak K. [2 ]
机构
[1] Chitkara Univ, Chitkara Coll Pharm, Patiala 140401, Punjab, India
[2] Univ Delhi, Delhi Inst Pharmaceut Sci & Res, Formerly Coll Pharm, Dept Pharmaceut,Sect 3, New Delhi 110017, India
关键词
broad-spectrum; fluoroquinolones; moxifloxacin; pKa; EXPERIMENTAL BACTERIAL KERATITIS; SUSTAINED OPHTHALMIC DELIVERY; AQUEOUS-HUMOR LEVELS; IN-VITRO ACTIVITY; CIPROFLOXACIN HYDROCHLORIDE; MOXIFLOXACIN; 0.5-PERCENT; GATIFLOXACIN; 0.3-PERCENT; DRUG-DELIVERY; INTRAOCULAR PENETRATION; PHYSICOCHEMICAL PROPERTIES;
D O I
10.1517/17425247.2013.772977
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Topical fluoroquinolones are used in ophthalmology to treat ocular infections. They are bactericidal and inhibit bacterial DNA replication by inhibiting DNA gyrase and topoisomerase. Fluoroquinolones possess two ionizable groups: a carboxylic group (pKa(1) = 5.5 - 6.34) and a heterocyclic group (pKa(2) = 7.6 - 9.3), in the nucleus, which acquire charge at pH above and below the isoelectric point (pI = 6.75 - 7.78). At isoelectric point, fluoroquinolones remain unionized and show enhanced corneal penetration but exhibit reduced aqueous solubility and the drug may precipitate from aqueous solution. Aqueous ophthalmic solutions of fluoroquinolones are obtained by using hydrochloride or mesylate salt which is acidic and irritating to the eyes. Hence, pH of the solution is kept between 5 and 7 to ensure aqueous solubility and minimum ocular irritation. Areas covered: This review gives an overview of various physicochemical and formulation factors affecting the ocular delivery of fluoroquinolones and strategies for getting higher ocular bioavailability for ocular delivery of fluoroquinolones. These strategies could be employed to improve efficacy of fluoroquinolones in eye preparation. Expert opinion: Broad-spectrum antibacterials, such as the ophthalmic fluoroquinolones, are powerful weapons for treating and preventing potentially sight-threatening infections. The fourth-generation fluoroquinolones have quickly assumed an outstanding place in the ophthalmic applications. Especially valuable for their broad-spectrum coverage against Gram-positive and Gram-negative organisms, these agents have become the anti-infective of preference for many ophthalmologists. Moxifloxacin seems to be a promising powerful molecule among all fluoroquinolones for treatment of bacterial infections.
引用
收藏
页码:691 / 711
页数:21
相关论文
共 50 条
  • [31] Polyoxyethylated nonionic surfactants and their applications in topical ocular drug delivery
    Jiao, Jim
    ADVANCED DRUG DELIVERY REVIEWS, 2008, 60 (15) : 1663 - 1673
  • [32] Topical delivery of ocular therapeutics: carrier systems and physical methods
    Souza, Joel G.
    Dias, Karina
    Pereira, Tatiana Aparecida
    Bernardi, Daniela Spuri
    Lopez, Renata F. V.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2014, 66 (04) : 507 - 530
  • [33] Challenges and solutions in topical ocular drug- delivery systems
    Ali, Maryam
    Byrne, Mark Edward
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2008, 1 (01) : 145 - 161
  • [34] Polyester nanocapsules as new topical ocular delivery systems for cyclosporin A
    Calvo, P
    Sanchez, A
    Martinez, J
    Lopez, MI
    Calonge, M
    Pastor, JC
    Alonso, MJ
    PHARMACEUTICAL RESEARCH, 1996, 13 (02) : 311 - 315
  • [35] Topical ocular drug delivery to inner ear disease and sinusitis
    Mimura, Tatsuya
    Funatsu, Hideharu
    Usui, Tomohiko
    Yamagami, Satoru
    Noma, Hidetaka
    Amano, Shiro
    SOUTHERN MEDICAL JOURNAL, 2006, 99 (11) : 1287 - 1289
  • [36] Hydrogel Ring for Topical Drug Delivery to the Ocular Posterior Segment
    Shikamura, Yuko
    Yamazaki, Yoshiko
    Matsunaga, Toru
    Sato, Takao
    Ohtori, Akira
    Tojo, Kakuji
    CURRENT EYE RESEARCH, 2016, 41 (05) : 653 - 661
  • [37] Determining the effect of ocular chemical injuries on topical drug delivery
    Begum, Ghazala
    Leigh, Thomas
    Stanley, David
    Logan, Ann
    Blanch, Richard James
    DRUG DELIVERY, 2021, 28 (01) : 2044 - 2050
  • [38] Fluoroquinolones and Ocular MRSA Infections
    Hong, Jiaxu
    Cao, Wenjun
    Xu, Jianjiang
    Sun, Xinghuai
    OPHTHALMOLOGY, 2013, 120 (01) : 218 - 219
  • [39] Fluoroquinolones - Place in ocular therapy
    Smith, A
    Pennefather, PM
    Kaye, SB
    Hart, CA
    DRUGS, 2001, 61 (06) : 747 - 761
  • [40] Protein Nanoparticles Laden In situ Gel for Topical Ocular Drug Delivery
    Pillai, Archana Rajan
    Prajapati, Bijal
    Dharamsi, Abhay
    CURRENT DRUG DELIVERY, 2024, 21 (01) : 38 - 51